Key result
Despite advances in therapy, patients surviving an acute coronary syndrome event still face an approximately 10% risk of recurrence over 12 months, highlighting the need for novel antithrombotics.
Why the study?
Does the addition of novel oral anticoagulants to single or dual antiplatelet therapy improve outcomes in patients after acute coronary syndrome?
Does the addition of novel oral anticoagulants to single or dual antiplatelet therapy improve outcomes in patients after acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
This editorial discusses the rationale and challenges of adding novel oral anticoagulants to antiplatelet therapy for secondary prevention after acute coronary syndrome.
This editorial refers to ‘New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis’†, by J. Oldgren et al., on page 1670 The past 20 years have seen substantial advances in the short- and long-term outcomes for patients after acute coronary syndromes (ACS). Improvements in therapy and adherence to guidelines have resulted in a reduction in hospital mortality from 10.4% in 1994 to 6.3% in 2006.1 Despite this, ∼17% of patients surviving an ACS event would experience recurrent events without secondary prophylaxis, and even with the newer antithrombotics there remains an ∼10% risk of recurrence over 12 months.2,3 The high rates of recurrence highlight the need for more effective secondary prevention strategies. Besides novel antiplatelet therapies.3−5 novel anticoagulants have also been developed. They have first been tested in atrial fibrillation and shown to be effective in stroke prevention.6 Given the positive results obtained with warfarin on top of aspirin after myocardial infarction published >10 years ago,7,8 they have also been tested on a large scale after ACS.9,10
No takes yet. Share an insight, caveat, or question.
Freek W.A. Verheugt (2013) conducted an editorial in Acute coronary syndromes (ACS). Combined antiplatelet and novel oral anticoagulant therapy was evaluated. Despite advances in therapy, patients surviving an acute coronary syndrome event still face an approximately 10% risk of recurrence over 12 months, highlighting the need for novel antithrombotics.
Synapse has enriched 10 related papers. Consider them for comparative context: